Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 19/20 | 0.34 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.31 |
| ▸ | HTR3B | O95264 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.31 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10103199 | 0.83 | HTR3E (0.42) | HSD11B1HTR3EHTR3BCHRNA7HTR3A | |
| SCHEMBL10103350 | 0.80 | HSD11B1 (0.43) | HSD11B1HTR3EHTR3BCHRNA7HTR3A | |
| SCHEMBL10103468 | 0.78 | HIF1A (0.40) | HSD11B1HTR3EHTR3BCHRNA7HTR3A | |
| SCHEMBL10103461 | 0.78 | HTT (0.36) | HSD11B1HTR3EHTR3BCHRNA7HTR3A | |
| SCHEMBL10103465 | 0.76 | TRPC3 (0.35) | HSD11B1HTR3EHTR3BCHRNA7HTR3A | |
| SCHEMBL10103445 | 0.76 | HSD11B1 (0.42) | HSD11B1HTR3EHTR3BCHRNA7HTR3A | |
| SCHEMBL10102950 | 0.75 | KDM1A (0.46) | HSD11B1 | |
| SCHEMBL10103196 | 0.75 | HSD11B1 (0.40) | HSD11B1 | |
| SCHEMBL10103112 | 0.74 | HSD11B1 (0.42) | HSD11B1 | |
| SCHEMBL10102943 | 0.73 | MAPK1 (0.39) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012015715-A1 | SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-02-02 | — | — | WO | disclosed |